5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Cipla Ltd.

•
cipla.comBSE: 500087NSE: CIPLA
Market Cap₹ 1,11,484 Cr.
Current Price
High / Low₹ 1,673 / 1,166
Stock P/E36.3
Book Value₹ 433
Price to Book2.89
Dividend Yield0.94 %
ROCE14.0 %
ROE10.6 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company comfortably covers its interest (241.2x coverage)
  • Company has a consistent dividend-paying track record
  • Company generates healthy free cash flow

CONS

  • Recent results are weak - TTM profit is down 42.1% versus prior year
  • Recurring exceptional / one-off items are inflating headline profit
  • Operating margins have contracted to 22.1% from 25.3%
  • Expensive relative to growth - PEG of 2.0

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTY100 LOWVOL30NIFTY100 EQL WGT
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.00128.3263558.070.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3,4613,7363,7983,4453,7523,9704,1354,2544,5024,4954,2573,8415,078
2,8463,0093,0253,2093,1413,3373,3093,4793,4223,7033,7773,6124,167
Operating Profit6167277732366116338267751,080792480229911
OPM %17.79%19.47%20.35%6.86%16.29%15.94%19.97%18.22%23.99%17.62%11.28%5.96%17.94%
158205169539214289189588271255172180243
Interest0795534363476
Depreciation136180135137138146143148146141153249169
Profit before Tax1,0981,2441,3811,2241,4301,5781,7041,7561,7441,6337365221,154
Tax %27.24%26.41%26.29%19.78%26.18%25.36%15.62%15.39%25.28%25.89%16.20%26.38%25.26%
Net Profit7999161,0189821,0561,1781,4381,4851,3031,211617385862
9.9011.3512.6112.1613.0814.5917.8118.3916.1314.997.644.7610.67

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
10,76811,39012,37412,65911,30315,38114,34516,57419,04518,98017,671
9,1729,1949,8729,9738,23511,67011,00012,09013,27014,54815,259
Operating Profit1,5962,1962,5022,6863,0673,7113,3454,4845,7754,4322,412
OPM %14.82%19.28%20.22%21.22%27.14%24.13%23.32%27.05%30.32%23.35%13.65%
1302575789142306672791,0711,283882850
Interest3912173645272220151919
Depreciation500530570600469547596588574658713
Profit before Tax1,1871,9112,4932,9642,7843,8043,0064,9476,4694,6364,046
Tax %17.86%23.17%24.25%21.80%26.56%24.23%28.66%24.92%20.27%24.18%24.01%
Net Profit9751,4691,8882,3182,0452,8832,1443,7145,1583,5153,074
EPS12.1118.2223.4128.7230.5736.6331.1246.0063.8643.52—
Dividend Payout %16.50%16.45%12.80%13.91%19.72%13.99%32.00%28.26%25.05%29.87%—

COMPOUNDED SALES GROWTH

10 Years:
5%
5 Years:
11%
3 Years:
10%

COMPOUNDED PROFIT GROWTH

10 Years:
9%
5 Years:
11%
3 Years:
18%

STOCK PRICE CAGR

10 Years:
9%
5 Years:
8%
3 Years:
3%
1 Year:
-12%

RETURN ON EQUITY

10 Years:
12%
5 Years:
13%
3 Years:
14%
Last Year:
11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jun 5

₹ 6.50

Rs.13.0000 per share(650%)Final Dividend

2025

Jun 27

₹ 1.50

Rs.3.0000 per share(150%)Special Dividend

2025

Jun 27

₹ 6.50

Rs.3.0000 per share(150%)Special Dividend

2024

Aug 2

₹ 6.50

Rs.13.0000 per share(650%)Final Dividend

2023

Jul 21

₹ 4.25

Rs.8.5000 per share(425%)Final Dividend

2022

Aug 8

₹ 2.50

Rs.5.0000 per share(250%)Dividend

2021

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Dividend

2020

Mar 19

Interim Dividend

2018

Aug 13

₹ 1.50

Rs.3.0000 per share(150%)Dividend

2017

Jul 26

₹ 1

Rs.2.0000 per share(100%)Dividend

2016

Sep 12

₹ 1

Rs.2.0000 per share(100%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161161161161161161161161162162
12,58013,89915,57817,20819,73122,31524,43827,76831,88633,977
45030011817414811514290174315
Trade Payables1,2981,5801,4811,6121,4951,5701,6391,6851,8842,062
1,0591,1091,0801,2511,4281,2871,2171,3491,4411,927
Total Liabilities15,54817,04818,41920,40622,96425,44927,59631,05335,54638,443
4,2354,3204,1274,0253,9433,8473,7473,6033,7655,192
Capital Work in Progress541435241256275186442581523720
4,2864,6375,8157,1909,72610,97411,90913,79417,35117,616
2,6543,0382,8683,0213,0863,4863,2773,2543,6074,354
00000002,6823,8603,397
Cash & Bank582281755238751,428966333278519
3,7744,3905,1925,3915,0605,5297,2546,8066,1616,645
Total Assets15,54817,04818,41920,40622,96425,44927,59631,05335,54638,443

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
2,5391,6391,9192,6834,4123,7074,1193,7273,3012,832
Cash from Investing-1,191-592-1,147-1,126-3,360-2,464-2,758-2,883-2,309-1,344
Cash from Financing-1,011-351-473-694-66-427-425-709-1,074-1,322
5173-15219834-117-148135-81166

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
30.9130.9229.1929.2029.1929.2129.2129.2129.21
27.8228.8026.6526.2825.2424.5423.9322.5520.20
24.6623.8727.4127.8828.9729.9730.4431.7034.34
Government0.000.000.000.000.000.000.000.000.00
16.4016.1916.5216.3816.3116.0016.1416.2615.95

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03
Press Release

2026-09-03 - Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".

2026-09-03
General Updates

2026-09-03 - Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.

2026-09-02
Copy of Newspaper Publication

2026-09-02 - Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

2026-08-31
Press Release

2026-08-31 - Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".

2026-08-28
General Updates

2026-08-28 - Cipla Limited has informed the Exchange about Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA

2026-08-27
Other Restructuring

2026-08-27 - Cipla Limited has informed the Exchange about Other Restructuring

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Cipla Limited has informed the Exchange about Schedule of meet

2026-08-26
ESOP/ESOS/ESPS

2026-08-26 - Cipla Limited has informed the Exchange regarding Allotment of 5281 Shares.

2026-08-25
General Updates

2026-08-25 - Cipla Limited has informed the Exchange about USFDA inspection at Company s manufacturing facility in Pithampur, India

News

Recent coverage and analyst commentary for CIPLA

Loading news…

🤖

AI Stock Analyst

Cipla Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login